DE69424441T2 - (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger - Google Patents

(2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger

Info

Publication number
DE69424441T2
DE69424441T2 DE69424441T DE69424441T DE69424441T2 DE 69424441 T2 DE69424441 T2 DE 69424441T2 DE 69424441 T DE69424441 T DE 69424441T DE 69424441 T DE69424441 T DE 69424441T DE 69424441 T2 DE69424441 T2 DE 69424441T2
Authority
DE
Germany
Prior art keywords
pharmaceutical
salts
disulfophenyl
tertiary butyl
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69424441T
Other languages
English (en)
Other versions
DE69424441D1 (de
Inventor
M Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of DE69424441D1 publication Critical patent/DE69424441D1/de
Application granted granted Critical
Publication of DE69424441T2 publication Critical patent/DE69424441T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69424441T 1993-12-23 1994-12-22 (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger Expired - Fee Related DE69424441T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (2)

Publication Number Publication Date
DE69424441D1 DE69424441D1 (de) 2000-06-15
DE69424441T2 true DE69424441T2 (de) 2000-10-12

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69424441T Expired - Fee Related DE69424441T2 (de) 1993-12-23 1994-12-22 (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger

Country Status (29)

Country Link
US (4) US5488145A (de)
EP (1) EP0736004B1 (de)
JP (3) JP3412821B2 (de)
KR (1) KR100370522B1 (de)
CN (1) CN1070176C (de)
AT (1) ATE192736T1 (de)
AU (1) AU679835B2 (de)
BR (2) BR9408378A (de)
CA (1) CA2179521C (de)
CZ (1) CZ289629B6 (de)
DE (1) DE69424441T2 (de)
DK (1) DK0736004T3 (de)
ES (1) ES2145264T3 (de)
FI (1) FI111718B (de)
GR (1) GR3034134T3 (de)
HK (2) HK1001768A1 (de)
HR (1) HRP950358B1 (de)
HU (1) HU221167B1 (de)
MY (1) MY114178A (de)
NO (1) NO306457B1 (de)
NZ (1) NZ279025A (de)
PL (1) PL185189B1 (de)
PT (1) PT736004E (de)
RU (1) RU2159231C2 (de)
SG (1) SG64903A1 (de)
SK (1) SK282403B6 (de)
TW (1) TW299315B (de)
UA (1) UA45964C2 (de)
WO (1) WO1995017876A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
CA2231812C (en) * 1995-09-11 2002-08-06 Hoechst Marion Roussel, Inc. Cyclic nitrones and pharmaceutical compositions containing them
WO1997019054A1 (en) 1995-11-17 1997-05-29 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
AU725432B2 (en) * 1996-04-17 2000-10-12 Centaur Pharmaceuticals, Inc. Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection
EP1021430A1 (de) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan-nitronverbindungen
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
US6015831A (en) * 1998-01-16 2000-01-18 Centaur Pharmaceuticals, Inc. Thiophene nitrone compounds
CN1291980A (zh) * 1998-01-16 2001-04-18 桑道药品有限公司 硫醚呋喃硝酮化合物
AU3000999A (en) * 1998-03-13 1999-09-27 Renovis, Inc. Inhibition of angiogenesis
WO1999059579A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
DK1616869T3 (da) 1999-01-25 2012-05-07 Nat Jewish Health Substituerede porphyriner og deres terapeutiske anvendelse
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
WO2001028578A2 (en) * 1999-10-22 2001-04-26 Wrair A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
WO2001051459A1 (en) * 2000-01-10 2001-07-19 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
SE0000056D0 (sv) * 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
JP2008519822A (ja) * 2004-11-12 2008-06-12 ニューロケム （インターナショナル） リミテッド アミロイド関連疾患を治療するための方法およびフッ素化組成物
JP2008520647A (ja) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Ｃｎｓおよびアミロイド関連疾患治療のための化合物
US8044100B2 (en) * 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
ATE481094T1 (de) * 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
ES2529050T3 (es) * 2006-07-25 2015-02-16 Hough Ear Institute Métodos para el tratamiento del trauma acústico agudo
CN103787927B (zh) 2006-10-12 2017-03-01 Bhi有限合资公司 递送3‑氨基‑1‑丙磺酸的方法、化合物、组合物和载体
WO2008078176A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US8425593B2 (en) 2007-09-26 2013-04-23 St. Jude Medical, Inc. Collapsible prosthetic heart valves
CA2715326C (en) 2008-02-12 2017-06-13 Tosk, Incorporated Toxicity-reducing nitrone adjuvants for doxorubicin and use of the same
EP2732817B1 (de) 2008-05-23 2016-08-24 National Jewish Health Verbindung zur Verwendung bei der Behandlung von Verletzungen aufgrund der Exposition gegenüber Phosgen oder Chlorgas
EP2326320B1 (de) 2008-09-02 2012-10-24 Oklahoma Medical Research Foundation 2,4-disulfonyl-phenyl-tert-butyl-nitron zur behandlung von gliomen
JP5762414B2 (ja) * 2009-08-24 2015-08-12 ハフ イヤ インスティテュート 急性音響外傷の治療方法
EP2670403B1 (de) 2011-02-04 2021-08-18 Hough Ear Institute Verfahren zur behandlung von gehirnverletzungen
US10576125B2 (en) 2016-10-31 2020-03-03 Hough Ear Institute Methods for enhancing synaptogenesis and neuritogenesis
EP3570826A4 (de) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. Formulierungen von n-acetylcystein und deren verwendungen
KR20200055722A (ko) 2017-09-20 2020-05-21 오클라호마 메디컬 리써치 화운데이션 약물 내성 신경아교종의 치료
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
JP2021523126A (ja) 2018-05-03 2021-09-02 ハフ イアー インスティテュート 蓄積した病理学的Ｔａｕタンパク質を低減する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
FI111718B (fi) 2003-09-15
AU1552795A (en) 1995-07-17
HK1008294A1 (en) 1999-05-07
JP2001010953A (ja) 2001-01-16
SK282403B6 (sk) 2002-01-07
CZ289629B6 (cs) 2002-03-13
US5780510A (en) 1998-07-14
HUT76788A (en) 1997-11-28
CN1070176C (zh) 2001-08-29
JP2004075696A (ja) 2004-03-11
SK78896A3 (en) 1997-09-10
UA45964C2 (uk) 2002-05-15
HRP950358B1 (en) 2001-04-30
SG64903A1 (en) 1999-05-25
EP0736004B1 (de) 2000-05-10
HK1001768A1 (en) 1998-07-10
ATE192736T1 (de) 2000-05-15
AU679835B2 (en) 1997-07-10
RU2159231C2 (ru) 2000-11-20
US5488145A (en) 1996-01-30
TW299315B (de) 1997-03-01
HU221167B1 (en) 2002-08-28
HU9601739D0 (en) 1996-08-28
CA2179521A1 (en) 1995-07-06
BR9408378A (pt) 1997-08-19
PT736004E (pt) 2000-09-29
DK0736004T3 (da) 2000-10-09
DE69424441D1 (de) 2000-06-15
CZ177596A3 (en) 1996-12-11
CA2179521C (en) 2002-03-19
JPH09507232A (ja) 1997-07-22
HRP950358A2 (en) 1997-08-31
US5508305A (en) 1996-04-16
MY114178A (en) 2002-08-30
EP0736004A1 (de) 1996-10-09
WO1995017876A2 (en) 1995-07-06
FI962589A (fi) 1996-08-20
GR3034134T3 (en) 2000-11-30
JP3412821B2 (ja) 2003-06-03
NO306457B1 (no) 1999-11-08
CN1156447A (zh) 1997-08-06
NO962637L (no) 1996-08-13
NO962637D0 (no) 1996-06-20
PL315154A1 (en) 1996-10-14
NZ279025A (en) 1998-02-26
BR1100626A (pt) 1999-11-23
KR100370522B1 (ko) 2003-05-16
ES2145264T3 (es) 2000-07-01
US5475032A (en) 1995-12-12
WO1995017876A3 (en) 1995-08-10
FI962589A0 (fi) 1996-06-20
PL185189B1 (pl) 2003-03-31

Similar Documents

Publication Publication Date Title
DE69424441D1 (de) (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
SE9503143D0 (sv) New preparation
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
ZA961137B (en) Solid active compound preparations.
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
CZ285522B6 (cs) Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
SE9602442D0 (sv) Administration of pharmaceuticals
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
EP0362941A3 (de) 4-Methyl und 4-Ethyl substituierte Pyrrolidin-2-one
SE9302218D0 (sv) New use
EP0380989A3 (en) Plaster for transdermal administration
WO2001009119A3 (en) Chemokine receptor antagonists
DE59410133D1 (de) Orale arzneiform enthaltend colestipol als träger mit sauren wirkstoffen und verfahren zu ihrer herstellung
DE69941359D1 (de) Cerebrospinal und vaskulär wirksame pharmazeutische zubereitung und verfahren zu ihrer herstellung
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
RU95122486A (ru) Средство для лечения тикозных гиперкинезов
MX9803271A (es) Uso de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,6-tetrahid ropiridina para la preparacion de farmacos para el tratamiento de esclerosis lateral aminotrofica.
MX9604201A (es) Nuevos derivados de piperidina.
YU49496B (sh) 2,4-disulfofenil butil nitron, njegove soli, i njihova primena kao farmaceutskih kompozicija

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee